|
| Clinical observation of Xiaoyan decoction adjusted dose of Astragalus combined with GP regimen in the treatment of non-small cell lung cancer |
| Hits 1634 Download times 1346 Received:July 30, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2017.09.04 |
| Key Words
Astragalus;dosage;bone marrow suppression;chemotherapy;non-small cell lung cancer |
| Author Name | Affiliation | E-mail | | ZHANG Li-li | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | HE Bin | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | WANG Yuan-yuan | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | JIA Ying-jie | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | jiayingjie1616@sina.com |
|
| Abstract
|
| [Objective] To observe Xiaoyan decoction adjusted dose of Astragalus combined with GP regimen in the treatment of non-small cell lung cancer.[Methods] Using completely randomized method, 90 patients in The First Affiliated Hospital of Tianjin University of traditional Chinese medicine of non-small cell lung cancer were randomly divided into treatment group (Xiaoyan decoction 60 g of Astragalus combined with GP) and control group (Xiaoyan decoction combined with GP). Different doses of Astragalus in Xiaoyan decoction of qi deficiency and stasis type of non-small cell lung cancer incidence of bone marrow suppression (level of WBC) and the influence of grading, cytokines, immune function, quality of life were observed.[Results] After 1 cycles of chemotherapy, the efficiency rate was 62.2% in the treatment group and 55.6% in the control group. There was no significant difference between two groups (P>0.05). In the aspect of suppression in bone marrow, WBC decreased level, recovery degree and incidence of bone marrow suppression in the treatment group was better than the control group (P<0.05). Treatment group was significantly better than the control group in bone marrow suppression grading. In immune function, level of CD3+, CD4+ and CD4+/CD8+ in treatment group were significantly increased than control group (P<0.05). In the cytokine after treatment, IL-6, GM-CSF of treatment group compared with the control group were increased significantly. There were statistically significant differences (P<0.05). In terms of quality of life, the change of KPS score between the two groups was statistically significant (P<0.05).[Conclusion] Increase the dosage of Astragalus in Xiaoyan decoction combined with chemotherapy in the treatment of non-small cell lung cancer can improve chemotherapy-induced bone marrow suppression, decreased immune function, cytokines reduce and the quality of life. Clinical efficiency is more obvious. |
|
|
|
|
|
|
|
